论文信息 - Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. - 字舞流文

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.

A. Rosenwald | M. Ziepert | N. Schmitz | G. Ott | G. Lenz | M. Loeffler | M. Dreyling | P. Borchmann | M. Bentz | B. Metzner | L. Truemper | G. Held | A. Viardot | M. Haenel | M. Nickelsen | B. Glass | B. Altmann | H. Horn | A. Staiger | F. Frontzek | F. Kroschinsky